Premium
Follicle‐stimulating hormone receptor expression in soft tissue sarcomas
Author(s) -
Renner Marcus,
Goeppert Benjamin,
Siraj Muhammad Ahsan,
Radu Aurelian,
Penzel Roland,
Wardelmann Eva,
Lehner Burkhard,
Ulrich Alexis,
Stenzinger Albrecht,
Warth Arne,
Vogel Monika Nadja,
Weichert Wilko,
Schirmacher Peter,
Mechtersheimer Gunhild,
Ghinea Nicolae
Publication year - 2013
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12135
Subject(s) - follicle stimulating hormone receptor , liposarcoma , sarcoma , soft tissue sarcoma , biology , mesenchymal stem cell , pathology , hormone receptor , ovary , follicle , cancer , medicine , endocrinology , breast cancer , genetics
Aims In adult humans, the follicle‐stimulating hormone receptor ( FSHR ) is expressed only in the granulosa cells of the ovary and the Sertoli cells of the testis. Recently, it has been shown that FSHR is expressed selectively on the surface of blood vessels in a wide range of tumours. So far, the expression of FSHR in mesenchymal tumours has not been studied. Methods and results We performed a semiquantitative evaluation of FSHR protein expression in a large cohort of soft tissue sarcomas ( STS ; n = 335), including 11 subtypes. FSHR ‐positive vessels were detected in all sarcoma subtypes analysed. Among liposarcomas, significantly more cases of dedifferentiated liposarcomas (28 of 44) showed FSHR expression compared to well‐differentiated liposarcomas ( WDLS ; four of 21; P < 0.001). Vessels in lipomas ( n = 9) and non‐neoplastic fat were FSHR ‐negative. FSHR expression was also detected in tumour cells of all sarcoma subtypes examined, with the lowest incidence in WDLS (three of 21; 14.3%) and the highest frequency in undifferentiated high‐grade pleomorphic sarcomas (41 of 60; 68.3%). Conclusions These data supplement the previously reported results of FSHR expression in endothelial cells of various cancer types and form a solid basis for further studies of FSHR in mesenchymal neoplasms.